MedTrace Logo

A Study to Evaluate the Pharmacokinetics After Administration of BR3003 and Co-administration of BR3003B and BR3003C.

NCT05411965 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2022-07-27

No results posted yet for this study

Summary

To perform a comparative evaluation on the pharmacokinetics and the safety after administration of "BR3003" and co-administration of "BR3003B" and "BR3003C" in healthy adults.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

BR3003(T)

Test drug (T):"BR3003" Boryung Pharmaceutical Co., Ltd.

DRUG

BR3003B(R1)

Reference drug 1 (R1): "BR3003B" of Celltrion Pharm, Inc.

DRUG

BR3003C(R2)

Reference drug 2 (R2): "BR3003C" of AstraZeneca Korea

Sponsors & Collaborators

  • Boryung Pharmaceutical Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Jaewoo Kim · H Plus Yangji Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-04-28
Primary Completion
2022-07-03
Completion
2022-07-03

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05411965 on ClinicalTrials.gov